Exscientia(EXAI.US)获英伟达投资的Recursion(RXRX.US)收购股价大涨16%

智通财经08-08

智通财经APP获悉，人工智能驱动的药物研发公司Recursion Pharmaceuticals(RXRX.US)已同意以6.88亿美元的价格全股票交易收购规模较小的竞争对手Exscientia(EXAI.US)。Recursion借助人工智能技术赋能新药研发，其支持者包括芯片制造商英伟达(NVDA.US)。公告发布后，截至发稿，Exscientia上涨了16%，而Recursion上涨了2%。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2457319307?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-08 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457319307","market":"sh","top_or_hot":-1,"title":"Exscientia(EXAI.US)获英伟达投资的Recursion(RXRX.US)收购 股价大涨16%","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，人工智能驱动的药物研发公司Recursion Pharmaceuticals(RXRX.US)已同意以6.88亿美元的价格全股票交易收购规模较小的竞争对手Exscientia(EXAI.US)。Recursion借助人工智能技术赋能新药研发，其支持者包括芯片制造商英伟达(NVDA.US)。公告发布后，截至发稿，Exscientia上涨了16%，而Recursion上涨了2%。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1161919.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exscientia(EXAI.US)获英伟达投资的Recursion(RXRX.US)收购 股价大涨16%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExscientia(EXAI.US)获英伟达投资的Recursion(RXRX.US)收购 股价大涨16%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-08 21:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1161919.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，人工智能驱动的药物研发公司Recursion Pharmaceuticals(RXRX.US)已同意以6.88亿美元的价格全股票交易收购规模较小的竞争对手Exscientia(EXAI.US)。Recursion借助人工智能技术赋能新药研发，其支持者包括芯片制造商英伟达(NVDA.US)。公告发布后，截至发稿，Exscientia上涨了16%，而Recursion上涨了2%。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1161919.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4592","symbol_name":"伊斯兰概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1161919.html","article_id":"2457319307","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457319307","pubTimestamp":1723124330,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，人工智能驱动的药物研发公司Recursion Pharmaceuticals已同意以6.88亿美元的价格全股票交易收购规模较小的竞争对手Exscientia。公告发布后，截至发稿，Exscientia上涨了16%，而Recursion上涨了2%。根据协议，Exscientia股东每持有一股普通股，将获得0.7729股Recursion A类普通股。交易完成后，Recursion股东将拥有合并后公司约74%的股份，而Exscientia股东将拥有其余股份。2023年7月，Recursion获得芯片制造商英伟达5000万美元的投资，推动了AI驱动生物制药股的上涨热潮。其同行Abcellera Biologics、Absci Corporation、Exscientia和Schrodinger皆应声上涨。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4592":"伊斯兰概念","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","IE00BDRTCR15.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC A","BK4567":"ESG概念","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","EXAI":"Exscientia plc","IE00B4JS1V06.HKD":"JANUS HENDERSON BALANCED \"A2\" (HKD) ACC","LU0056508442.USD":"贝莱德世界科技基金A2","BK4587":"ChatGPT概念","IE0004086264.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"A\" (USD) ACC","IE00BFSS7M15.SGD":"Janus Henderson Balanced A Acc SGD-H","NVDA":"英伟达","BK4543":"AI","IE0034235295.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"A\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","BK4527":"明星科技股","LU0072462426.USD":"贝莱德全球配置 A2","IE0004091025.USD":"BNY MELLON GLOBAL OPPORTUNITIES \"B\" (USD) ACC","IE00BHPRN162.USD":"BNY MELLON BLOCKCHAIN INNOVATION \"B\" (USD) ACC","BK4579":"人工智能","IE00BDCRKT87.USD":"PINEBRIDGE GLOBAL DYNAMIC ASSET ALLOCATION \"ADC\" (USD) INC","BK4141":"半导体产品","LU0079474960.USD":"联博美国增长基金A","BK4550":"红杉资本持仓","BK4588":"碎股","BK4503":"景林资产持仓","RXRX":"Recursion Pharmaceuticals, Inc.","BK4551":"寇图资本持仓","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BJJMRY28.SGD":"Janus Henderson Balanced A Inc SGD","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","BK4581":"高盛持仓","IE0005OL40V9.USD":"JANUS HENDERSON BALANCED \"A6M\" (USD) INC","IE00B5949003.HKD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","IE00BWXC8680.SGD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A5\" (SGD) ACC","LU0061474705.USD":"THREADNEEDLE (LUX) GLOBAL DYNAMIC REAL RETURN \"AU\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","BK4529":"IDC概念","IE00BD6J9T35.USD":"NEUBERGER BERMAN NEXT GENERATION MOBILITY \"A\" (USD) ACC","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC"},"translate_title":"Exscientia (EXAI.US) was acquired by Recursion (RXRX.US) invested by Nvidia, and its stock price soared 16%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1,"EXAI":1,"NVDA":0.7},"content_text":"智通财经APP获悉，人工智能驱动的药物研发公司Recursion Pharmaceuticals(RXRX.US)已同意以6.88亿美元的价格全股票交易收购规模较小的竞争对手Exscientia(EXAI.US)。Recursion借助人工智能技术赋能新药研发，其支持者包括芯片制造商英伟达(NVDA.US)。公告发布后，截至发稿，Exscientia上涨了16%，而Recursion上涨了2%。根据协议，Exscientia股东每持有一股普通股，将获得0.7729股Recursion A类普通股。部分股份将以现金支付。这笔交易预计将于2025年初完成，将为合并后的实体提供约8.5亿美元的现金，为其未来三年的运营提供资金。交易完成后，Recursion股东将拥有合并后公司约74%的股份，而Exscientia股东将拥有其余股份。合并后的Recursion将由联合创始人兼首席执行官克里斯•吉布森(Chris Gibson)领导，而Exscientia的临时首席执行官David Hallett将出任首席科学官。2023年7月，Recursion获得芯片制造商英伟达5000万美元的投资，推动了AI驱动生物制药股的上涨热潮。其同行Abcellera Biologics(ABCL.US)、Absci Corporation(ABSI.US)、Exscientia和Schrodinger(SDGR.US)皆应声上涨。今年早些时候，该公司还推出了一台名为BioHive-2的英伟达超级计算机，该设备有助于加速药物发现的进程。目前，主要制药商正加倍投入人工智能以促进药物开发，希望快速寻找临床试验患者或减少测试药物所需的人数，这既能帮助加快药物开发进程，又可能节省乃至数百万美元。Recursion首席研发官纳贾特·汗(Najat Khan)表示，“在从生物学到化学的发现中使用端到端的方式，将Recursion和Exscientia结合在一起是非常互补的。这将能够更好更快地生产药物，也是我们正努力做的。”","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457319307"}

Exscientia(EXAI.US)获英伟达投资的Recursion(RXRX.US)收购 股价大涨16%

精彩评论

Exscientia(EXAI.US)获英伟达投资的Recursion(RXRX.US)收购股价大涨16%